CLDA
Clinical Data, Inc.NASDAQ
CLDA is defunct.
  • Feb. 22, 2011, 8:07 AM

    Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder treatment Viibryd, which sent shares up more than 50%. (PR)

    | Feb. 22, 2011, 8:07 AM
  • Feb. 3, 2011, 9:10 AM

    Premarket gainers: HNSN +42%. FRG +38%. SFLY +17%. GMCR +17%. BJ +14%. NETL +10%. ENTR +7%. PSTI +5%. CLDA +5%. LTD +5%. JCP +4%. KEM +4%. TTM +4%. BX +4%. APKT +4%. YUM +4%.
    Losers: ANW -12%. TZOO -11%. RDN -10%. ISIL -8%. GBG -5%. PCX -5%. GLP -4%. RDS.A -4%. ARR -4%.

    | Feb. 3, 2011, 9:10 AM
  • Jan. 24, 2011, 1:52 PM
    Eight underperforming stocks with increasing put/call ratios, according to Kapitall: Clinical Data (CLDA), Home Inns & Hotels (HIHM), Supervalu (SVU), Volcom (VLCM), Orbitz (OWW), Ctrip.com (CTRP), Clearwire (CLWR), Taseko Mines (TGB). Contrarians may believe these stocks are set to rally based on a high number of open put positions relative to call positions.
    | Jan. 24, 2011, 1:52 PM
  • Jan. 24, 2011, 9:24 AM

    Clinical Data (CLDA) announces that its major depressive disorder treatment Viibryd received approval from the FDA. The biotech company says the drug should be available in U.S. pharmacies in Q2. CLDA +67.3% premarket. (PR)

    | Jan. 24, 2011, 9:24 AM